Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-06-20
1995-10-03
Prescott, Arthur C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514 8, 514 25, 536 41, 536 174, 536 176, 536 21, 424122, A61K 3710
Patent
active
054552400
ABSTRACT:
The present invention relates to compositions and methods for preventing pneumococcal infection. In particular, the invention relates to identification of the major reception for Streptococcus pneumoniae on activated human cells, and diagnostic and therapeutic compositions and methods based thereon. In particular, the invention relates to the discovery that platelet activating factor (PAF) receptor is an adhesive ligand for pneumococcal adherence to activated lung epithelial and venous endothelial (i.e., host) cells. Accordingly, the present invention is directed to a method for preventing or treating an infection with Streptococcus pneumoniae by administering an antagonist of platelet activating factor receptor. The invention further relates to recognition that adherence to activated cells also involves a carbohydrate ligand found on such activated cells. Thus, a method for inhibiting pneumococcal adherence may further comprise administering an amount of carbohydrate containing an N-acetyl-D-glucosamine motif. It has been found that resting lung epithelial and venous endothelial cells bear two classes of receptors containing different carbohydrate motifs. Thus, the invention further provides for administering an amount of a second carbohydrate selected from the group consisting of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif, a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif, and a mixture thereof. In addition, the invention provides pharmaceutical compositions comprising such agents that inhibit binding of pneumococci to human cells. In a specific example, platelet activating factor receptor antagonists and disaccharides are shown to inhibit binding of pneumococci to activated lung epithelial cells and venous endothelial cells, as well as cells transfected with the platelet activating factor receptor, in vitro.
REFERENCES:
patent: 5132286 (1992-07-01), Malabarba et al.
patent: 5304556 (1994-04-01), Yamamoto et al.
patent: 5358938 (1994-10-01), Cai et al.
Cabellos et al., 1992, J. Clin. Invest. 90:612.
Tomasz and Saukkonen, 1989, Ped. Infect. Dis. J. 8:902-3.
Tuomanen et al., 1987, Am. Rev. Respir. Dis. 135:869-74.
Tuomanen et al., 1985, J. Infect. Dis. 151:535-40.
Tuomanen et al., 1985, J. Infect. Dis. 151:859-68.
Rozdzinski et al., 1993, J. Exp. Med. 178:917-24.
Geelen et al., 1993, Infect. Immun. 61:1538-43.
Tuomanen et al., 1988, J. Exp. Med. 168:267-77.
Krivan et al., 1988, Proc. Natl. Acad. Sci. USA 85:6157-61.
Andersson et al., 1983, J. Exp. Med. 158:559-70.
Hwang et al., 1989, Mol. Pharmacol. 35:48-58.
Hwang and Lam, 1991, LIPIDS 26:1148-53.
Wissner et al., 1986, J. Med. Chem. 29:328-33.
Gerard and Gerard, 1994, J. Immunol. 152:793-800.
Chao and Olson, 1993, Biochem. J. 292:617-629.
Kunz et al., 1992, J. Biol. Chem. 267:9101-6.
Dinarello and Wolff, 1993, N. Eng. J. Med. 328:106-113.
van de Kar et al., 1992, Blood 80:2755-64.
Cundell Diana R.
Gerard Norma P.
Tuomanen Elaine I.
Beth Israel Hospital Association
Prescott Arthur C.
The Rockefeller University
LandOfFree
Modulators of pneumococcal adhesion to cellular targets involvin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of pneumococcal adhesion to cellular targets involvin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of pneumococcal adhesion to cellular targets involvin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1077472